View More Recent Stories
-
Capricor Therapeutics (CAPR) Appoints Michael Binks as Chief Medical Officer
-
Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
Cantor Fitzgerald Reiterates Overweight Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Tops Q4 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel
-
Cantor Fitzgerald says 15% of biotech companies down 40% or more
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
-
Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Piper Sandler Reiterates Overweight Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
-
Jones Trading Starts Capricor Therapeutics (CAPR) at Buy
-
Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c, provides outlook
-
Capricor Therapeutics (CAPR) files for 2.8M share offering by selling stockholders
-
Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight
-
Capricor Therapeutics (CAPR) Prices $75M Share Offering at $17/sh
-
After-hours movers: CSX Corp., Kinder Morgan, Alcoa and more
-
Capricor Therapeutics (CAPR) Announces Proposed Public Offering of Common Stock
-
Capricor Therapeutics (CAPR) Files $150M Mixed Shelf
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of DMD
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
-
Increasing unusual option volume: CAPR VTNR ASHR AVTR ITUB SFIX APLD SRE FULC
-
Capricor Therapeutics (CAPR) October 10 and 15 calls as shar price up 35%
-
Capricor Therapeutics (CAPR) PT Raised to $25 at Maxim Group
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Increasing unusual call option volume: SMAR MCHI TME ASHR TIGR BBIO POET ROIV CAPR
-
Capricor Therapeutics (CAPR) Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR), 'Accelerated Approval May Be In The Cards'
-
Capricor Therapeutics (CAPR) to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer
-
Capricor Therapeutics (CAPR) Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-
Capricor Therapeutics (CAPR) Tops Q2 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
Capricor Therapeutics (CAPR) announces FDA has scheduled Pre-BLA meeting for deramiocel to treat DMD
-
Capricor Therapeutics (CAPR) Files $150M Mixed Shelf
-
Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002 Program
